Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8137753 | 0.91 | PPARG (0.48) | PPARGPPARA | |
| SCHEMBL9387175 | 0.91 | PPARG (0.49) | PPARGPPARA | |
| SCHEMBL6052112 | 0.89 | PPARG (0.51) | PPARGPPARA | |
| SCHEMBL6052101 | 0.88 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL8135014 | 0.88 | PPARG (0.46) | PPARGPPARA | |
| SCHEMBL8140558 | 0.87 | PPARG (0.47) | PPARGPPARA | |
| SCHEMBL8132217 | 0.87 | PPARG (0.45) | PPARGPPARA | |
| SCHEMBL8139708 | 0.84 | PPARG (0.41) | PPARGPPARA | |
| SCHEMBL8136523 | 0.83 | PPARG (0.40) | PPARGPPARA | |
| SCHEMBL7723265 | 0.83 | PPARG (0.48) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0605228-A1 | Thiazolidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1994-07-06 | — | — | EP | claimed |
| EP-1047423-B1 | NOVEL APOPTOSIS INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2006-05-10 | — | — | EP | disclosed |
| US-20020086883-A1 | Compound, such as pioglitazone, having an insulin sensitivity enhancing activity for the prophylaxis or treatment of a disease mediated by promotion of apoptosis, such as neurodegenerative disease | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-07-04 | — | — | US | disclosed |
| US-6399639-B1 | ADMINISTERING A 2,4-THIADIAZOLIDINEDIONE COMPOUND | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-04 | — | — | US | disclosed |
| US-6087384-A | TREATING PROPHYLAXIS AND TREATMENT OF A DISEASE ASSOCIATE WITH DEATH OF CELLS CAUSED BY VIRAL DISEASES, MYELODYSPLASIS, NEURODEGENERATIVE, ISCHEMIC AND HEPATIC DISEASES WITH A COMPOUND HAVING AN INSULIN SENSITIVITY ENHANCING ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| EP-0605228-B1 | Thiazolidinedione derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-03-01 | — | — | EP | disclosed |
| US-5489602-A | HYPOGLYCEMIC AND HYPOLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-06 | — | — | US | disclosed |
| EP-0605228-A1 | Thiazolidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1994-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086883-A1 | Compound, such as pioglitazone, having an insulin sensitivity enhancing activity for the prophylaxis or treatment of a disease mediated by promotion of apoptosis, such as neurodegenerative disease | IRS1, IAPP, AIFM1 | PPARG 51/4885PPARA 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.